#151197

Anti-Clathrin heavy chain [STo 3H9]

Cat. #151197

Anti-Clathrin heavy chain [STo 3H9]

Cat. #: 151197

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Clathrin heavy chain

Class: Monoclonal

Application: WB

Reactivity: Human

Host: Mouse

£312.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Sharon Tooze

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Clathrin heavy chain [STo 3H9]
  • Research fields: Cell biology;Cell signaling and signal transduction
  • Clone: STo 3H9
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: WB
  • Description: Clathrin is a component of clathrin-coated pits and vesicles involved in receptor-mediated endocytosis.
  • Immunogen: Human Clathrin heavy chain
  • Isotype: IgM

Target Details

  • Target: Clathrin heavy chain
  • Target background: Clathrin is a component of clathrin-coated pits and vesicles involved in receptor-mediated endocytosis.

Applications

  • Application: WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.